We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
The latest trading session saw CRISPR Therapeutics AG (CRSP - Free Report) ending at $41.17, denoting a -1.84% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.22%. Elsewhere, the Dow saw a downswing of 0.03%, while the tech-heavy Nasdaq depreciated by 0.33%.
The company's shares have seen a decrease of 20.9% over the last month, not keeping up with the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.31, marking an 8.39% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $5.21 million, showing a 942% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.13 per share and a revenue of $55.61 million, demonstrating changes of -18.2% and +49.04%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.9% lower within the past month. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
The latest trading session saw CRISPR Therapeutics AG (CRSP - Free Report) ending at $41.17, denoting a -1.84% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.22%. Elsewhere, the Dow saw a downswing of 0.03%, while the tech-heavy Nasdaq depreciated by 0.33%.
The company's shares have seen a decrease of 20.9% over the last month, not keeping up with the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.31, marking an 8.39% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $5.21 million, showing a 942% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of -$5.13 per share and a revenue of $55.61 million, demonstrating changes of -18.2% and +49.04%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.9% lower within the past month. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.